1
|
Kuo KH, Oluyadi A, Shao H, Morris S, Zaidi AU, Beers EJV, Thein SL. A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MITAPIVAT IN PATIENTS WITH SICKLE CELL DISEASE. Hematol Transfus Cell Ther 2022. [DOI: 10.1016/j.htct.2022.09.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
2
|
Kalakonda N, Cavallo F, Follows G, Goy A, Vermaat J, Casasnovas O, Lavee O, Maerevoet M, Zijlstra J, Bakshi S, Bouabdallah R, Choquet S, Gurion R, Hill B, Jaeger U, Sancho J, Schuster M, Thieblemont C, De la Cruz F, Egyed M, Mishra S, Offner F, Vassilakopoulos T, Warzocha K, Oluyadi A, McCarthy D, Ma X, Corona K, Shah J, Van Den Neste E, Canales M. A PHASE 2B STUDY OF SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL). Hematol Oncol 2019. [DOI: 10.1002/hon.31_2629] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- N. Kalakonda
- Molecular and Clinical Cancer Medicine; University of Liverpool; Liverpool United Kingdom
| | - F. Cavallo
- Molecular Biotechnology and Health Sciences; Aziena Ospedaliero - Universitaria Città della Salute e della Scienza di Torino; Turin Italy
| | - G. Follows
- Haematology; Cambridge University Hospitals NHS Foundation Trust Addenbrooke's Hospital; Cambridge United Kingdom
| | - A. Goy
- Oncology; Hackensack University Medical Center; Hackensack United States
| | - J. Vermaat
- Hematology; Leiden University Medical Center; Leiden Netherlands
| | | | - O. Lavee
- Hematology; St. Vincent's Hospital Sydney; Darlinghurst Australia
| | - M. Maerevoet
- Hematology; Service Hématologie, Institut Bordet; Bruxelles Belgium
| | - J. Zijlstra
- Hematology; Amsterdam UMC; Amsterdam Netherlands
| | - S. Bakshi
- Medical Oncology; Dr. B. R. A. Institute Rotary Cancer Hospital; New Delhi India
| | - R. Bouabdallah
- Oncology/Hematology; Institut Paoli-Calmettes; Marseille France
| | - S. Choquet
- Hematology; Hospital Pitie Salpetriere; Paris France
| | - R. Gurion
- Hematology; Rabin MC; Petah Tiqwa Israel
| | - B. Hill
- Hematology and Medical Oncology; Cleveland Clinic Main Campus; Cleveland United States
| | - U. Jaeger
- Medicine I; Medical University of Vienna; Vienna Austria
| | - J. Sancho
- Clinical Hematology; Hospital Germans Trias i Pujol; Barcelona Spain
| | - M. Schuster
- Medicine; Stony Brook University; Stony Brook United States
| | | | - F. De la Cruz
- Hematology; Hospital Universitario Virgen del Rocío; Sevilla Spain
| | - M. Egyed
- Hematology; Teaching Hospital Mór Kaposi; Kaposvár Hungary
| | - S. Mishra
- Medical Oncology; Institute of Medical Sciences & SUM Hospital; Bhubaneswar India
| | | | | | - K. Warzocha
- Hematology; Instytut Hematologii i Transfuzjologii; Warszawa Poland
| | - A. Oluyadi
- Clinical Development; Karyopharm Therapeutics Inc.; Newton United States
| | - D. McCarthy
- Clinical Operations; Karyopharm Therapeutics Inc.; Newton United States
| | - X. Ma
- Biostatistics; Karyopharm Therapeutics Inc.; Newton United States
| | - K. Corona
- Medical Affairs; Karyopharm Therapeutics Inc.; Newton United States
| | - J. Shah
- Clinical Development; Karyopharm Therapeutics Inc.; Newton United States
| | - E. Van Den Neste
- Hematology; Cliniques Universitaires Saint-Luc; Brussels Belgium
| | - M. Canales
- Medicine; Hospital Universitario La Paz; Madrid Spain
| |
Collapse
|